List view / Grid view
Dr Cyril Clarke at ICON Biotech reveals how biomarkers are transforming early-phase clinical trials by offering valuable insights into the safety and efficacy of novel therapies.
Gene silencing offers a promising approach to treating rare neurological diseases like H-ABC. With clinical trials on the horizon, find out how targeted therapies could bring real hope to patients and families.
US researchers say new mechanism could lead to new drugs and therapies to treat normal cognitive decline in aging.
Individuals with higher levels of lean muscle may have a reduced risk of developing Alzheimer's disease. While further research is needed to understand the underlying biological pathways and implications for clinical practice, these findings shed light on the potential role of lean muscle in protecting brain health.
Using rodent models, the researchers emphasized the potential of newly generated neurons in adulthood to serve as therapy for addressing the functional deficits and pathology associated with Alzheimer's disease.
Researchers have found a way to ensure that new Alzheimer’s medications are delivered to the right place in the body and at the right timepoint in disease progression, so that they have the best effect.
Scientists from Rice University are using fluorescence lifetime to shed new light on a peptide associated with Alzheimer’s disease.
In this article, Drug Target Review’s Izzy Wood and Ria Kakkad share some of the most ground-breaking moments from drug discovery this year.
German researchers have designed peptides that bind to amyloidogenic proteins linked to Alzheimer’s and type 2 diabetes, to effectively suppress both cytotoxic amyloid aggregation and amyloid cross-accelerating interactions.
Researchers have connected the loss of alpha-B insulin receptors in brain microvessels as contributors to insulin resistance and cognitive decline, with Alzheimer’s disease.
A new MIT study highlights ailing neurons may activate an inflammatory response from the brain’s microglia immune cells.
UCLA-led team discovers that using early-stage stem cells is a key to producing structures that are reliable models of disease.
Researchers have successfully characterised a part of the brain that shows the earliest accumulation of tau protein, an important biomarker for the development of Alzheimer's disease.
Scientists at UTHealth Houston have developed an agonistic antibody that reduced the amyloid pathology in mice with Alzheimer’s disease.
A new study has shown how tau weakens transmission across synapses in the brains of mice, providing insight into Alzheimer's.
